Cargando…

Panax ginseng as an adjuvant treatment for Alzheimer's disease

Longevity in medicine can be defined as a long life without mental or physical deficits. This can be prevented by Alzheimer's disease (AD). Current conventional AD treatments only alleviate the symptoms without reversing AD progression. Recent studies demonstrated that Panax ginseng extract imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyeon-Joong, Jung, Seok-Won, Kim, Seog-Young, Cho, Ik-Hyun, Kim, Hyoung-Chun, Rhim, Hyewhon, Kim, Manho, Nah, Seung-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190533/
https://www.ncbi.nlm.nih.gov/pubmed/30337800
http://dx.doi.org/10.1016/j.jgr.2017.12.008
_version_ 1783363591443841024
author Kim, Hyeon-Joong
Jung, Seok-Won
Kim, Seog-Young
Cho, Ik-Hyun
Kim, Hyoung-Chun
Rhim, Hyewhon
Kim, Manho
Nah, Seung-Yeol
author_facet Kim, Hyeon-Joong
Jung, Seok-Won
Kim, Seog-Young
Cho, Ik-Hyun
Kim, Hyoung-Chun
Rhim, Hyewhon
Kim, Manho
Nah, Seung-Yeol
author_sort Kim, Hyeon-Joong
collection PubMed
description Longevity in medicine can be defined as a long life without mental or physical deficits. This can be prevented by Alzheimer's disease (AD). Current conventional AD treatments only alleviate the symptoms without reversing AD progression. Recent studies demonstrated that Panax ginseng extract improves AD symptoms in patients with AD, and the two main components of ginseng might contribute to AD amelioration. Ginsenosides show various AD-related neuroprotective effects. Gintonin is a newly identified ginseng constituent that contains lysophosphatidic acids and attenuates AD-related brain neuropathies. Ginsenosides decrease amyloid β-protein (Aβ) formation by inhibiting β- and γ-secretase activity or by activating the nonamyloidogenic pathway, inhibit acetylcholinesterase activity and Aβ-induced neurotoxicity, and decrease Aβ-induced production of reactive oxygen species and neuroinflammatory reactions. Oral administration of ginsenosides increases the expression levels of enzymes involved in acetylcholine synthesis in the brain and alleviates Aβ-induced cholinergic deficits in AD models. Similarly, gintonin inhibits Aβ-induced neurotoxicity and activates the nonamyloidogenic pathway to reduce Aβ formation and to increase acetylcholine and choline acetyltransferase expression in the brain through lysophosphatidic acid receptors. Oral administration of gintonin attenuates brain amyloid plaque deposits, boosting hippocampal cholinergic systems and neurogenesis, thereby ameliorating learning and memory impairments. It also improves cognitive functions in patients with AD. Ginsenosides and gintonin attenuate AD-related neuropathology through multiple routes. This review focuses research demonstrating that ginseng constituents could be a candidate as an adjuvant for AD treatment. However, clinical investigations including efficacy and tolerability analyses may be necessary for the clinical acceptance of ginseng components in combination with conventional AD drugs.
format Online
Article
Text
id pubmed-6190533
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61905332018-10-18 Panax ginseng as an adjuvant treatment for Alzheimer's disease Kim, Hyeon-Joong Jung, Seok-Won Kim, Seog-Young Cho, Ik-Hyun Kim, Hyoung-Chun Rhim, Hyewhon Kim, Manho Nah, Seung-Yeol J Ginseng Res Review Article Longevity in medicine can be defined as a long life without mental or physical deficits. This can be prevented by Alzheimer's disease (AD). Current conventional AD treatments only alleviate the symptoms without reversing AD progression. Recent studies demonstrated that Panax ginseng extract improves AD symptoms in patients with AD, and the two main components of ginseng might contribute to AD amelioration. Ginsenosides show various AD-related neuroprotective effects. Gintonin is a newly identified ginseng constituent that contains lysophosphatidic acids and attenuates AD-related brain neuropathies. Ginsenosides decrease amyloid β-protein (Aβ) formation by inhibiting β- and γ-secretase activity or by activating the nonamyloidogenic pathway, inhibit acetylcholinesterase activity and Aβ-induced neurotoxicity, and decrease Aβ-induced production of reactive oxygen species and neuroinflammatory reactions. Oral administration of ginsenosides increases the expression levels of enzymes involved in acetylcholine synthesis in the brain and alleviates Aβ-induced cholinergic deficits in AD models. Similarly, gintonin inhibits Aβ-induced neurotoxicity and activates the nonamyloidogenic pathway to reduce Aβ formation and to increase acetylcholine and choline acetyltransferase expression in the brain through lysophosphatidic acid receptors. Oral administration of gintonin attenuates brain amyloid plaque deposits, boosting hippocampal cholinergic systems and neurogenesis, thereby ameliorating learning and memory impairments. It also improves cognitive functions in patients with AD. Ginsenosides and gintonin attenuate AD-related neuropathology through multiple routes. This review focuses research demonstrating that ginseng constituents could be a candidate as an adjuvant for AD treatment. However, clinical investigations including efficacy and tolerability analyses may be necessary for the clinical acceptance of ginseng components in combination with conventional AD drugs. Elsevier 2018-10 2018-01-12 /pmc/articles/PMC6190533/ /pubmed/30337800 http://dx.doi.org/10.1016/j.jgr.2017.12.008 Text en © 2018 The Korean Society of Ginseng, Published by Elsevier Korea LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Kim, Hyeon-Joong
Jung, Seok-Won
Kim, Seog-Young
Cho, Ik-Hyun
Kim, Hyoung-Chun
Rhim, Hyewhon
Kim, Manho
Nah, Seung-Yeol
Panax ginseng as an adjuvant treatment for Alzheimer's disease
title Panax ginseng as an adjuvant treatment for Alzheimer's disease
title_full Panax ginseng as an adjuvant treatment for Alzheimer's disease
title_fullStr Panax ginseng as an adjuvant treatment for Alzheimer's disease
title_full_unstemmed Panax ginseng as an adjuvant treatment for Alzheimer's disease
title_short Panax ginseng as an adjuvant treatment for Alzheimer's disease
title_sort panax ginseng as an adjuvant treatment for alzheimer's disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190533/
https://www.ncbi.nlm.nih.gov/pubmed/30337800
http://dx.doi.org/10.1016/j.jgr.2017.12.008
work_keys_str_mv AT kimhyeonjoong panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT jungseokwon panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT kimseogyoung panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT choikhyun panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT kimhyoungchun panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT rhimhyewhon panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT kimmanho panaxginsengasanadjuvanttreatmentforalzheimersdisease
AT nahseungyeol panaxginsengasanadjuvanttreatmentforalzheimersdisease